Firm to host meeting get in touch with and webcast these days at 8:30 a.m. EDT

CARMIEL, Israel, Aug. 15, 2022 /PRNewswire/ — Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical corporation targeted on the enhancement, creation and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant mobile-based protein expression process, currently noted financial results for the next quarter ended June 30, 2022 and provided a company update on modern company and regulatory developments.

“Positive topline success from our period III Harmony medical demo of PRX-102 for the therapy of adult patients with Fabry condition have been announced last April. The clinical examine report (CSR) for the demo is now complete,” mentioned Dror Bashan, Protalix’s President and Chief Government Officer. “The closing assessment of the Balance study, which was designed to consider the efficacy and protection of 1 mg/kg of PRX–102 administered each and every other 7 days in contrast to agalsidase beta in clients earlier taken care of with agalsidase beta, confirms the good topline results and favorable tolerability profile. The final results from the Harmony review spotlight our assurance that PRX–102 has the probable to develop into an vital therapy choice for people with Fabry sickness. We are enthusiastic to shift nearer to likely approval of PRX–102 and commercial launch, and thank our workforce users and external companions for their continued help.”

2022 2nd Quarter and The latest Organization Highlights

Company Developments

• On June 30, 2022, the Enterprise announced the appointment of Shmuel “Muli” Ben Zvi, Ph.D. to the Board of Administrators. Dr. Ben Zvi is serving as the new Chairman of the Audit Committee and as a member of the Compensation Committee.

Next Quarter 2022 Money Highlights

• The Enterprise recorded revenues from marketing items of $3.4 million for the 3 months finished June 30, 2022, an enhance of $.2 million, or 6%, compared to revenues of $3.2 million for the very same period of 2021.
• Revenue from licenses and R&D products and services for the 3 months finished June 30, 2022 have been $5.4 million, an enhance of $2.2 million, or…